

JAPAN PATENT OFFICE

This is to certify that the annexed is a true copy of the following application as filed with this Office.

Date of Application : January 20, 2004

Application Number : Patent Application No. 2004-012265

Applicant : Iichiro SHIMOMURA
Yuji MATSUZAWA
Tohru FUNAHASHI
SANKYO COMPANY, LIMITED

Date : March 16, 2004

Commissioner,
Japan Patent Office

Yasuo IMAI

Official Seal

Name of Document	Patent Application
Docket Number	2004003KB
Address To :	Commissioner, Patent Office
International Patent Classification	A61P 9/00
Inventor	
Address	33-11, Higashitoyonakacho 1-chome, Toyonaka-shi, Osaka Japan
Name	Ichiro SHIMOMURA
Inventor	
Address	21-23, Hibarigaokayamate 2-chome, Takarazuka-shi, Hyogo Japan
Name	Yuji MATSUZAWA
Inventor	
Address	7-9, Takanodai 2-chome, Suita-shi, Osaka Japan
Name	Tohru FUNAHASHI
Inventor	
Address or Domicile	c/o SANKYO COMPANY, LIMITED 2-58, Hiromachi 1-chome, Shinagawa-ku, Tokyo Japan
Name	Toshiyuki TAKAGI
Patent Applicant	
Identification Number	503007759
Name	Ichiro SHIMOMURA
Patent Applicant	
Identification Number	599101070
Name	Yuji MATSUZAWA
Patent Applicant	
Identification Number	503098528
Name	Tohru FUNAHASHI
Patent Applicant	
Identification Number	000001856
Name	SANKYO COMPANY, LIMITED
Agent	
Identification Number	100081400
Patent Attorney Name	Akio OHNO

2004-012265

Indication of Official Fee

Prepayment Register Number 010216

Amount to be paid 21,000 yen

List of Materials to be submitted

Name of Material Scope of Claim for Patent 1

Name of Material Specification 1

Name of Material Abstract 1

Number of General Power of Attorney 9704937

[Name of Document] Scope of Claim for Patent

[Claim 1]

An adiponectin production enhancer comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s).

[Claim 2]

An adiponectin production enhancer according to claim 1, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

[Claim 3]

An adiponectin production enhancer according to claim 1, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.

[Claim 4]

An adiponectin production enhancer according to claim 1, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 5]

An adiponectin production enhancer according to claim 1, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 6]

An adiponectin production enhancer according to claim 1, wherein the HMG-CoA reductase inhibitor is pravastatin.

[Claim 7]

A therapeutic or preventive agent of hypoadiponectinemia comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 8]

A therapeutic or preventive agent of hypoadiponectinemia according to claim 7, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 9]

A therapeutic or preventive agent of hypoadiponectinemia according to claim 7, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 10]

A therapeutic or preventive agent of hypoadiponectinemia according to claim 7, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Claim 11]

An improving agent of insulin resistance comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 12]

An improving agent of insulin resistance according to claim 11, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 13]

An improving agent of insulin resistance according to claim 11, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 14]

An improving agent of insulin resistance according to claim 11, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Claim 15]

A therapeutic or preventive agent of hypertension comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 16]

A therapeutic or preventive agent of hypertension according to claim 15, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 17]

A therapeutic or preventive agent of hypertension according to claim 15, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 18]

A therapeutic or preventive agent of hypertension according to claim 15, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Claim 19]

A therapeutic or preventive agent of obesity comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 20]

A therapeutic or preventive agent of obesity according to claim 19, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 21]

A therapeutic or preventive agent of obesity according to claim 19, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 22]

A therapeutic or preventive agent of obesity according to claim 19, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Claim 23]

A therapeutic agent of arteriosclerosis comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 24]

A therapeutic agent of arteriosclerosis according to claim 23, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 25]

A therapeutic agent of arteriosclerosis according to claim 23, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 26]

A therapeutic agent of arteriosclerosis according to claim 23, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Claim 27]

A therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia, comprising as an active ingredient one

or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 28]

A therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia according to claim 27, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 29]

A therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia according to claim 27, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 30]

A therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia according to claim 27, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Claim 31]

A therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome, comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

[Claim 32]

A therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome according to claim 31, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

[Claim 33]

A therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome according to claim 31, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

[Claim 34]

A therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome according to claim 31, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[Name of Document] SPECIFICATION

[Title of the Invention] ADIPONECTIN PRODUCTION ENHANCER

[Technical Field]

[0001]

The present invention relates to an adiponectin production enhancer; a therapeutic or preventive agent of hypoadiponectinemia; an improving agent of insulin resistance; a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract, and coronary artery disease), hypertension, obesity or arteriosclerosis; and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, containing as an active ingredient one or more HMG-CoA reductase inhibitor(s).

[Background Art]

[0002]

Adiponectin is a protein that is specifically produced and secreted from adipocytes, and is intimately involved in energy balance and glucose or lipid metabolism (Maeda, K. et al., Biochemical and Biophysical Research Communications, 1996, 221, 286-289). In actuality, in patients with circulatory diseases, diabetes, obesity, etc., blood adiponectin concentration decreases (Ouchi, N. et al., Circulation, 1999, 100, 2473-2476; Lindsay, R.S. et al., Lancet, 2002, 360, 57-58; Arita, Y. et al., Biochemical and Biophysical Research Communications, 1999, 257, 79-83). In addition, kidney disease patients exhibiting low blood adiponectin concentrations are known

to have a higher mortality rate due to circulatory diseases than patients with high blood adiponectin concentrations (Zoccali, C. et al., Journal of American Society of Nephrology, 2002, 13, 134-141). Thus, disease states having decreased blood adiponectin concentrations, namely hypoadiponectinemia, are thought to be intimately related to lifestyle diseases such as circulatory diseases (arteriosclerosis, hypertension, etc.), diabetes or obesity, and are believed to be one of their basic causes (Weyer, C. et al., The Journal of Clinical Endocrinology & Metabolism, 2001, 86, 1930-1935; Hotta, K. et al., Diabetes, 2001, 50, 1126-1133). Thus, the therapeutic or preventive agent of hypoadiponectinemia is also useful in the therapeutic or preventive agent of the aforementioned lifestyle diseases caused by hypoadiponectinemia.

[0003]

Adiponectin is known to have actions of suppressing adhesion of THP-1 cells to vascular endothelial cells, expression of adhesion molecules, differentiation of vascular smooth muscle cells, macrophage foam cell formation, and the like (Ouchi, N. et al., Circulation, 1999, 100, 2473-2476; Ouchi, N. et al., Circulation 2001, 103, 1057-1063; Arita, Y. et al., Circulation 2002, 105, 2893-2898; Ouchi, N. et al., Circulation, 2000, 102, 1296-1301; Yokota, T. et al., Blood, 2000, 96, 1723-1732). These biological phenomena are intrinsic phenomena that occur during the initial stage of the onset of arteriosclerosis (Ross, R. et al., Nature, 1993, 362, 801-809), and the inhibitory effects demonstrated by adiponectin on these phenomena are extremely useful for the therapeutic or preventive agent of arteriosclerosis. In addition, increasing adiponectin concentration has been shown to have therapeutic effects on arteriosclerosis in an

actual animal model (Okamoto, Y. et al., Circulation, 2002, 106, 2767-2770).

[0004]

In addition, adiponectin is also intimately related to insulin resistance and diabetes (Kondo, H. et al., Diabetes, 2002, 51, 2325-2328). Insulin resistance is known to increase in the presence of hypoadiponectinemia (Weyer, C. et al., The Journal of Clinical Endocrinology & Metabolism, 2001, 86, 1930-1935; Hotta, K. et al., Diabetes, 2001, 50, 1126-1133), and in an animal model, administration of adiponectin is known to demonstrate glucose metabolism ameliorative action by having effects of improving insulin resistance, suppressing glucose production in the liver, and the like (Yamauchi, T., et al., Nature Medicine, 2001, 7, 941-946; Berg, A.H. et al., Nature Medicine, 2001, 7, 947-953; Combs, T.P. et al., Clinical Investigation, 2001, 108, 1875-1881). Thus, increasing blood adiponectin concentration is useful for the therapeutic or preventive agent of diabetes and diabetes complications caused thereby.

[0005]

Diseases states that exhibit increased insulin resistance, namely insulin resistance syndrome, are considered to be a principal cause of diabetes as well as the fundamental cause of lifestyle diseases such as circulatory diseases (arteriosclerosis, hypertension, etc.) or obesity (McVeigh, G.E. et al., Current Diabetes Reports, 2003, 3, 87-92; Chaudhuri, A. et al., Current Diabetes Reports, 2002, 2, 305-310; Sorisky, A. et al., American Journal of Therapeutics, 2002, 9, 516-521), and improvement of insulin resistance plays an important role in the therapeutic or preventive agent of the aforementioned lifestyle diseases. In other words, improvement of insulin

resistance is also useful for the therapeutic or preventive agent of the aforementioned lifestyle diseases caused by insulin resistance syndrome. As previously mentioned, since adiponectin has an action of improving insulin resistance (Yamauchi, T. et al., Nature Medicine, 2001, 7, 941-946), it is useful for the therapeutic or preventive agent of insulin resistance syndrome, as well as the therapeutic or preventive agent of diabetes, diabetes complications, circulatory diseases (arteriosclerosis, hypertension, etc.) or obesity caused by insulin resistance syndrome.

[0006]

On the basis of the above, a medicament that enhances adiponectin production has an action of improving insulin resistance and is useful as an adiponectin production enhancer, a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract, and coronary artery disease), hypertension, obesity or arteriosclerosis, and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome.

[0007]

Although certain types of thiazolidine dione compounds or cannabinoid CB₁ receptor antagonists are known to demonstrate action of enhancing adiponectin production (for example, see Non patent document 1 or 2), HMG-CoA reductase inhibitors have not been known to demonstrate adiponectin production enhancing action or therapeutic or preventive

effects for hypoadiponectinemia.

[0008]

HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors are well-known hyperlipemia therapeutic medicaments (for example, US Patent No. 4346227, etc.). Statins are typical HMG-CoA reductase inhibitors, and disease preventive effects in humans have been confirmed in various clinical studies. For example, pravastatin has been reported to demonstrate effects (preventive effects) of suppressing the onset of arteriosclerosis, coronary artery disease and diabetes in a clinical study targeted at hyperlipemia patients (for example, see Non patent documents 3 to 5).

[0009]

However, HMG-CoA reductase inhibitors are not known to demonstrate therapeutic effects for arteriosclerosis or diabetes, or therapeutic or preventive effects for diabetes complications, hypertension or obesity.

[0010]

In addition, although certain types of HMG-CoA reductase inhibitors have been reported to have an action of improving insulin resistance (for example, see Non patent documents 6 to 8), pravastatin and rosuvastatin have heretofore not been known to have an action of improving insulin resistance.

[Non patent document 1] Maeda, N. et al., Diabetes, 2001, 50, 2094-2099.

[Non patent document 2] Bensaid, M. et al., Molecular Pharmacology, 2002, 360, 1623-1630.

[Non patent document 3] MacMahon, S. et al., Circulation, 1998, 97, 1784-1790.

[Non patent document 4] Shepherd, J. et al., Lancet, 2002, 360, 1623-1630.

[Non patent document 5] Freeman, D.J. et al., Circulation, 2001, 103, 357-362.

[Non patent document 6] Mangaloglu, L. et al., Metabolism, Clinical and Experimental, 2002, 51, 409-418.

[Non patent document 7] Cingozbay, B.Y. et al., Journal of International Medical Research, 2002, 30, 21-25.

[Non patent document 8] Paolisso, G. et al., Atherosclerosis, 2000, 150, 121-127.

[Disclosure of the invention]

[Problem to be solved by the invention]

[0011]

The inventors of the present invention found that an HMG-CoA reductase inhibitor has superior adiponectin production enhancing action, and is useful as an enhancement agent of adiponectin production, a therapeutic or preventive agent of hypoadiponectinemia, an improving of insulin resistance, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract, and coronary artery disease), hypertension, obesity or arteriosclerosis; and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, thereby leading to completion of the present invention.

[Means for solving the problem]

[0012]

The present invention provides, an enhancement agent of adiponectin production, a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy,

neuropathy, cataract, and coronary artery disease), hypertension, obesity or arteriosclerosis, and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, containing as an active ingredient one or more HMG-CoA reductase inhibitor(s).

[0013]

The present invention is:

- (1) an adiponectin production enhancer comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s),
- (2) an adiponectin production enhancer as (1), wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin,
- (3) an adiponectin production enhancer as (1), wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor,
- (4) an adiponectin production enhancer as (1), wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,
- (5) an adiponectin production enhancer as (1), wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,
- (6) an adiponectin production enhancer as (1), wherein the HMG-CoA reductase inhibitor is pravastatin,
- (7) a therapeutic or preventive agent of hypoadiponectinemia comprising as an active ingredient one

or more water-soluble HMG-CoA reductase inhibitor(s),
(8) a therapeutic or preventive agent of hypoadiponectinemia as (7), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(9) a therapeutic or preventive agent of hypoadiponectinemia as (7), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,

(10) a therapeutic or preventive agent of hypoadiponectinemia as (7), wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin,

(11) an improving agent of insulin resistance comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s),

(12) an improving agent of insulin resistance as (11), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(13) an improving agent of insulin resistance as (11), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,

(14) an improving agent of insulin resistance as (11), wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin,

(15) a therapeutic or preventive agent of hypertension comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s),

(16) a therapeutic or preventive agent of hypertension as (15), wherein the water-soluble HMG-CoA reductase inhibitor

is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(17) a therapeutic or preventive agent of hypertension as (15), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,

(18) a therapeutic or preventive agent of hypertension as (15), wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin,

(19) a therapeutic or preventive agent of obesity comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s),

(20) a therapeutic or preventive agent of obesity as (19), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(21) a therapeutic or preventive agent of obesity as (19), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,

(22) a therapeutic or preventive agent of obesity as (19), wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin,

(23) a therapeutic agent of arteriosclerosis comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s),

(24) a therapeutic agent of arteriosclerosis as (23), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(25) a therapeutic agent of arteriosclerosis as (23), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,

(26) a therapeutic agent of arteriosclerosis according to claim 23, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin,

(27) a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia, comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s),

(28) a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia as (27), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(29) a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia as (27), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin,

(30) a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia as (27), wherein the water-soluble HMG-

CoA reductase inhibitor is pravastatin,

(31) a therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome, comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s),

(32) a therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome as (31), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof,

(33) a therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome as (31), wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin and

(34) a therapeutic or preventive agent of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome as (31), wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

[0014]

There are no particular restrictions on the HMG-CoA reductase inhibitor(s) serving as an active ingredient compound of the present invention provided it is a compound that demonstrates HMG-CoA reductase inhibitory action, examples of which include compounds having HMG-CoA reductase inhibitory action, pharmacologically acceptable salts thereof, or pharmacologically acceptable esters thereof as described in Japanese Patent Application (Kokai) No. Sho 57-2240 (US Patent No. 4346227), Japanese Patent Application (Kokai) No. Sho 57-163374 (US Patent No. 4231938), Japanese Patent Application (Kokai) No. Sho 56-122375 (US Patent No. 4444784), Japanese Patent Application

(Kokai) No. Sho 60-500015 (US Patent No. 4739073), Japanese Patent Application (Kokai) No. Hei 1-216974 (US Patent No. 5006530), Japanese Patent Application (Kokai) No. Hei 3-58967 (US Patent No. 5273995), Japanese Patent Application (Kokai) No. Hei 1-279866 (US Patent Nos. 5854259 and 5856336) or Japanese Patent Application (Kokai) No. Hei 5-178841 (US Patent No. 5260440), preferably pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin or rosuvastatin, more preferably pravastatin or rosuvastatin, and most preferably pravastatin.

[0015]

For an HMG-CoA reductase inhibitor serving as an active ingredient compound of the present invention, a water-soluble HMG-CoA reductase inhibitor such as pravastatin and rosuvastatin is preferable. In the present invention, a water-soluble HMG-CoA reductase inhibitor is an HMG-CoA reductase inhibitor in which the logarithm of the partition coefficient measured between phosphate buffer solution (pH 7.0 to 8.0, preferably pH 7.0 to 7.5, and more preferably pH 7.0) and 1-octanol [$\log(\text{test substance concentration in 1-octanol phase} / \text{test substance concentration in buffer solution phase})$] is 1.0 or less (preferably 0.5 or less, and more preferably 0.0 or less) (McTaggart, F. et al., The American Journal of Cardiology, 2001, 87, 28B-32B; Chapman, M. J. et al., Atherosclerosis Supplements, 2002, 33-37; Shimada, Y. et al., Progress in Medicine, 1998, 18, 957-962). The aforementioned partition coefficient can be measured according to ordinary methods (Partition Coefficient (n-octanol/water), OECD Guidelines for Testing of Chemicals, Section 1, Physical Chemical Properties, Paris, 1981, 107; Shimada, Y. et al., Progress in Medicine, 1998, 18, 957-962) or similar methods thereto.

[0016]

In addition, for an HMG-CoA reductase inhibitor serving as an active ingredient compound of the present invention, pravastatin or derivative thereof, or rosuvastatin or derivative thereof, is preferable. In the present invention, a derivative of pravastatin is a compound having HMG-CoA reductase inhibitory action, a pharmacologically acceptable salt thereof or ester thereof as described in Japanese Patent Application (Kokai) No. Sho 57-2240 (US Patent No. 4346227), while a derivative of rosuvastatin is a compound having HMG-CoA reductase inhibitory action, a pharmacologically acceptable salt thereof or ester thereof as described in Japanese Patent Application (Kokai) No. Hei 5-178841 (US Patent No. 5260440).

[0017]

Pravastatin is (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(S)-2-methylbutyryloxy]-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid, and includes its pharmacologically acceptable salts or esters (for example, monosodium salt of the aforementioned pravastatin, etc.) as described in Japanese Patent Application (Kokai) No. Sho 57-2240 (US Patent No. 4346227). Lovastatin is (+)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthyl (S)-2-methylbutyrate, and includes its pharmacologically acceptable salts or esters as described in Japanese Patent Application (Kokai) No. Sho 57-163374 (US Patent No. 4231938). Simvastatin is (+)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthyl 2,2-dimethylbutyrate, and includes its pharmacologically

acceptable salts or esters as described in Japanese Patent Application (Kokai) No. Sho 56-122375 (US Patent No. 4444784). Fluvastatin is (\pm) -(3R*,5S*,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, and includes its pharmacologically acceptable salts or esters (for example, monosodium salt of the aforementioned fluvastatin, etc.) as described in Japanese Patent Application (Kokai) No. Sho 60-500015 (US Patent No. 4739073). Cerivastatin is (3R,5S,6E)-7-[4-(4-fluorophenyl)-2,6-di-(1-methylethyl)-5-methoxymethylpyridin-3-yl]-3,5-dihydroxy-6-heptenoic acid, and includes its pharmacologically acceptable salts or esters (for example, monosodium salt of the aforementioned cerivastatin, etc.) as described in Japanese Patent Application (Kokai) No. Hei 1-216974 (US Patent No. 5006530). Atorvastatin is (3R,5S)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-phenylaminocarbonyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, and includes its pharmacologically acceptable salts or esters (for example, 1/2 calcium salt of the aforementioned atorvastatin, etc.) as described in Japanese Patent Application (Kokai) No. Hei 3-58967 (US Patent No. 5273995). Pitavastatin is (E)-3,5-dihydroxy-7-[4'-(4"-fluorophenyl)-2'-cyclopropylquinolin-3'-yl]-6-heptenoic acid, and includes its pharmacologically acceptable salts or esters (for example, 1/2 calcium salt of the aforementioned pitavastatin, etc.) as described in Japanese Patent Application (Kokai) No. Hei 1-279866 (US Patent Nos. 5854259 and 5856336). Rosuvastatin is (+)-(3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid, and includes its pharmacologically acceptable salts or esters (for example, 1/2 calcium salt of the aforementioned rosuvastatin, etc.) as described in


Japanese Patent Application (Kokai) No. Hei 5-178841 (US Patent No. 5260440).

[0018]


The following indicates the two-dimensional structural formulas of major HMG-CoA reductase inhibitors.

[0019]


[Chemical formula 1]




Pravastatin




Lovastatin




Simvastatin



Fluvastatin




Cerivastatin



Atorvastatin

[0020]

[Chemical formula 2]



Pitavastatin

[0021]

In the case where the aforementioned HMG-CoA reductase inhibitor has an asymmetric carbon, all of its racemate, its optical isomers and mixtures thereof are included in the HMG-CoA reductase inhibitor of the present invention. In addition, hydrates of the aforementioned HMG-CoA reductase inhibitors are also included in the HMG-CoA reductase inhibitor of the present invention.

[0022]

For an HMG-CoA reductase inhibitor serving as an active ingredient compound in the present invention, one type of compound can be used alone, or a mixture of two or more types of compounds can be used. In the case of using a mixture of two or more types of compounds, the compounds can be used simultaneously or each of compounds can be used separately at different times.

[Effect of the invention]

[0023]

Since the HMG-CoA reductase inhibitor(s) serving as an active ingredient of the present invention has superior adiponectin production enhancing action, it is useful as a therapeutic or preventive agent of diseases wherein blood adiponectin concentration decreases due to the occurrence of that disease, and diseases that occur due to a decrease

in blood adiponectin concentration (and preferably diseases wherein blood adiponectin concentration decreases due to the occurrence of that disease). The HMG-CoA reductase inhibitor(s) serving as an active ingredient of the present invention is useful as a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis, and, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome,

preferably for a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, more preferably for a therapeutic or preventive agent of hypoadiponectinemia, and a therapeutic or preventive agent of diabetes or arteriosclerosis caused by hypoadiponectinemia. In addition, the aforementioned therapeutic or preventive agent is preferably for warm-blooded animals, and more preferably for humans.

An HMG-CoA reductase inhibitor serving as an active ingredient of the present invention can easily be prepared in accordance with known methods [for example, Japanese Patent Application (Kokai) No. Sho 57-2240 (US Patent No.

4346227), Japanese Patent Application (Kokai) No. Sho 57-163374 (US Patent No. 4231938), Japanese Patent Application (Kokai) No. Sho 56-122375 (US Patent No. 4444784), Japanese Patent Application (Kokai) No. Sho 60-500015 (US Patent No. 4739073), Japanese Patent Application (Kokai) No. Hei 1-216974 (US Patent No. 5006530), Japanese Patent Application (Kokai) No. Hei 3-58967 (US Patent No. 5273995), Japanese Patent Application (Kokai) No. Hei 1-279866 (US Patent Nos. 5854259 and 5856336), Japanese Patent Application (Kokai) No. Hei 5-178841 (US Patent No. 5260440), etc.] or similar methods thereto.

[0024]

In the case of using the HMG-CoA reductase inhibitor(s) serving as an active ingredient of the present invention as a pharmaceutical (a therapeutic or preventive agent of the aforementioned diseases), it can be administered in the form of a bulk medicament of the pharmaceutical itself; or it can be orally administered in a formulation such as tablet, capsule, granules, pill, powder, liquid, syrup, troche, suspension, emulsion, etc. or be parenterally administered in a formulation such as an injection, suppository or patch, etc., which formulations are made by mixing the HMG-CoA reductase inhibitor with a suitably pharmacologically acceptable excipient, binder and so forth. An oral administration is preferred.

[0025]

These formulations are prepared using well-known methods using additives such as excipients, binders, disintegrants, lubricants, emulsifiers, stabilizers, corrigents, diluents, injection solvents and so forth.

[0026]

An excipient may be, for example, an organic excipient or inorganic excipient. Examples of organic excipients

include sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbitol; starch derivatives such as cornstarch, potato starch, alpha starch, dextrin and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, and internally-crosslinked sodium carboxymethyl cellulose; gum arabic; dextran; and, pullulan. Examples of inorganic excipients include silicic acid salt derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate, and magnesium metasilicate aluminate; phosphoric acid salts such as calcium phosphate; carbonic acid salts such as calcium carbonate; and sulfuric acid salts such as calcium sulfate.

[0027]

Examples of binders include the compounds as described for the aforementioned excipient; gelatin; polyvinylpyrrolidone; and, polyethylene glycol.

[0028]

Examples of disintegrants include the compounds as described for the aforementioned excipient; chemically modified starch or cellulose derivatives such as crosscarmellose sodium and sodium carboxymethyl starch; and, crosslinked polyvinylpyrrolidone.

[0029]

Examples of lubricants include talc; stearic acid; metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as bee gum and spermaceti; boric acid; glycol; DL-leucine; carboxylic acids such as fumaric acid and adipic acid; carboxylic acid sodium salts such as sodium benzoate; sulfates such as sodium sulfate; lauryl sulfates such as sodium lauryl

sulfate and magnesium lauryl sulfate; silicic acids such as anhydrous silicic acid and silicic acid hydrate; and the above starch derivatives as for the aforementioned excipients.

[0030]

Examples of emulsifiers include colloidal clays such as bentonite and bee gum; metal hydroxides such as magnesium hydroxide and aluminium hydroxide; anionic surfactants such as sodium lauryl sulfate and calcium stearate; cationic surfactants such as benzalkonium chloride; and, nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, and sucrose fatty acid ester.

[0031]

Examples of stabilizers include parahydroxybenzoic acid esters such as methyl paraben and propyl paraben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenols such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid.

[0032]

Examples of corrigents include ordinarily used sweeteners, sour flavourings, fragrances, etc.

[0033]

Examples of diluents include water, ethanol, propylene glycol, ethoxyisostearyl alcohol and polyoxyethylene sorbitan fatty acid ester.

[0034]

Examples of injection solvents include water, ethanol and glycerin.

[0035]

The HMG-CoA reductase inhibitor(s) serving as an active ingredient of the present invention can be

administered to a warm-blooded animal (and particularly a human). The dose can be varied depending on various conditions such as the symptoms and age of the patient. In the case of oral administration, 0.1 mg (preferably 0.5 mg) as a lower limit and 1000 mg (preferably 500 mg) as an upper limit can be administered once to six times per day for a human adult depending on the symptoms. In the case of parenteral administration, 0.01 mg (preferably 0.05 mg) as a lower limit and 100 mg (preferably 50 mg) as an upper limit can be administered once to six times per day for a human adult depending on the symptoms.

[Best mode for carrying out the invention]

[0036]

The following provides a more detailed explanation of the present invention by indicating Examples and Formulation examples, but the present invention is not limited thereto.

[Examples]

[0037]

(Example 1) Adiponectin production enhancing action (in vitro)

(1) Cell culturing

Preadipocyte cell line 3T3-L1 was purchased from the American Type Culture Collection (ATCC). The 3T3-L1 cells were plated onto a 24-well, collagen-coated plate and cultured to saturation in growth medium (DMEM, 25 mM glucose, 10% FCS, 100 u/ml penicillin, 0.1 mg/ml streptomycin) under conditions of 37°C and 5% CO₂. Five days after cell proliferation had reached a saturated state, the medium was replaced with medium (DMEM, 25 mM glucose, 10% FCS, 100 u/ml penicillin, 0.1 mg/ml streptomycin) to which had been added 1 μ M insulin, 0.5 mM

3-isobutyl-1-methylxanthine and 1 μ M dexamethazone to initiate adipocyte differentiation. Two days later, the medium was replaced with growth medium containing 1 μ M insulin followed by additionally culturing the cells for 2 days. Subsequently, the medium was replaced with fresh growth medium every 3 days, and the 3T3-L1 adipocytes were prepared on day 10 after the start of differentiation.

[0038]

Test compounds that were poorly soluble in water were used after dissolving in DMSO. Test compounds that were easily soluble in water were dissolved in sterile water followed by addition of the same amount of DMSO as that used for the aforementioned poorly water-soluble test compounds. In addition, in the case of test compounds that are poorly soluble in water, the test compound may be dissolved in ethanol and used following the addition of 0.1 N aqueous sodium hydroxide solution after shaking as necessary.

[0039]

After allowing the 3T3-L1 cells to adequately differentiate into adipocytes, a test compound was added to the medium to a final concentration of 10 μ M followed by culturing the cells for 48 hours. The cells were additionally cultured for 24 hours after replacing the medium. Following culturing, the cells were used for measurement of adiponectin mRNA, while the supernatant was used for measurement of the amount of adiponectin secreted.

(2) Measurement of adiponectin mRNA

RNA was extracted from cells that had been treated with a test compound using Sepasol (Nacalai-Tesque). cDNA was then synthesized using the ThermoScript Reverse Transcriptase Kit (registered trade mark: Invitrogen) by

using the extracted RNA as a template. The synthesized cDNA was amplified using FastStrand DNA Master SYBR Green I (Roche Diagnostics), and the amplified PCR product was detected with LightCycler (Roche Diagnostics). The sequences and SEQ ID numbers in the sequence listing to be described later for the primers used and the 36B4 used as an internal control are shown below.

[0040]

Adiponectin: 5'-GATGGCAGAGATGGCACTCC-3'

(SEQ ID NO. 1)

5'-CTTGCCAGTGCTGCGGTCAT-3'

(SEQ ID NO. 2)

36B4: 5'-GCTCCAAGCAGATGCAGCA-3'

(SEQ ID NO. 3)

5'-CCGGATGTGAGGCAGCAG-3'

(SEQ ID NO. 4)

The adiponectin mRNA amount was measured according to quantitative RT-PCR. The amounts of adiponectin mRNA in the groups in which pravastatin and rosuvastatin were used as test compounds were 1.6 times and 1.3 times higher, respectively, than those in the control group.

(3) Measurement of amount of secreted adiponectin

Secretion of adiponectin into culture supernatant was detected by Western blotting. 0.5 µl of recovered culture supernatant were fractionated by 12.5% SDS-polyacrylamide gel electrophoresis, and the protein following fractionation was transferred to a PVDF membrane (Millipore). Subsequently, anti-adiponectin antibody was bound to the PVDF membrane and after washing with PBS, was reacted with antibody conjugated with Horseradish peroxidase. After washing the PVDF membrane, the adiponectin bands were detected using ECL Detection Reagents (Amersham-Pharmacia). The bands were quantified

with a densitometer (Molecular Devices).

[0041]

The amounts of secreted adiponectin were analyzed by Western blotting. The amounts of secreted adiponectin in the groups in which pravastatin and rosuvastatin were used as test compounds were 1.7 times and 1.6 times higher, respectively, than those in the control group.

[0042]

On the basis of the results described in (2) and (3) above, an HMG-CoA reductase inhibitor serving as an active ingredient of the present invention was determined to have superior action of enhancing the production of adiponectin, and to be useful as an enhancement agent of adiponectin production, a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, etc.

(Example 2) Adiponectin production enhancing action (in vivo) and glucose uptake enhancing action

(1) Administration of Pravastatin to mice in feed

(i) Test animals

C57BL/6J mice (male, age 5 weeks) were purchased from Clea Japan, and used in the test after acclimating to the test environment for 1 week. The mice were housed 5 animals to a cage and given unrestricted access to feed (F2, Funabashi farm) and water.

(ii) Schedule

The body weights of the animals were measured and blood samples were collected on the day the test started,

and the animals were divided into two groups of 5 animals per cage based on their body weights and blood glucose levels. Blood samples were collected at the start of the test and in weeks 6, 11 and 15 after the start of the test. Blood samples were collected from the tail vein in an amount equal to one heparinized capillary tube.

(iii) Administration method

Pravastatin powder was added to the F2 powder to 0.06% (wt/wt), uniformly mixed and provided to the animals in individual cages. The amount of feed and general behaviour were checked at least once a day.

(iv) Measurement

Blood glucose levels were measured on the days when blood samples were collected. Adiponectin levels were measured simultaneously for all blood samples following completion of administration. The Glucose CII-Test Wako (Wako) and Mouse/Rat Adiponectin ELISA Kit (Otsuka Pharmaceutical) were respectively used for measurement.

(2) Insulin tolerance test using Pravastatin-dosed mice

A group administered with pravastatin by mixing in feed for 15 weeks and a non-dosed group of C57BL/6J mice (n=5) were fasted for 2 hours. After measuring the body weight of each animal, insulin (Humalin, Lilly) was administered intraperitoneally at 0.5 u/kg, and blood samples were collected from the tail vein immediately before the start of administration and at 15, 30, 60 and 90 minutes after the start of administration followed by measurement of blood glucose levels.

(3) Glucose uptake test using isolated adipocytes from Pravastatin-dosed mice

(i) Epididymal adipose tissue was excised from a group administered with pravastatin for 16 weeks and a non-dosed group of C57BL/6J mice (n=5). The excised adipose tissue

was handled under conditions of 37°C at all times. The adipose tissue was cut into small pieces with a scissors, followed by the addition of medium (DMEM, 1 mM sodium pyruvate, 25 mM HEPES pH 7.4, 0.1% BSA, 100 u/ml penicillin, 0.1 mg/ml streptomycin) containing 1 mg/ml of collagenase I (Worshington), and shaking at 37°C and 80 rpm. Following the reaction, 2.5 volumes of the aforementioned medium were added, the adipocytes were screened out by passing the cell suspension through a 260 µm mesh sieve, and again passed through a 100 µm mesh sieve to prepare an adipocyte suspension.

(ii) The glucose uptake test was carried out in the manner as described below. 100 µl of the aforementioned cell suspension, 90 µl of medium and 10 µl of insulin solution were added to a polystyrene tube, while stirring gently to uniformly distribute the adipocytes in each tube, and the adipocytes were cultured for 30 minutes at 30°C.

Subsequently, 0.6 µCi of ³H-labeled 2-deoxyglucose was added and allowed to react for 30 minutes. Following the reaction, the cell suspension was immediately transferred to a centrifuge tube containing silicone oil and centrifuged. After cutting out the oil layer of the upper layer containing adipocytes with a knife, it was transferred to a glass vial containing 4 ml of Hionic Fluor (Perkin-Elmer) liquid scintillation counter cocktail followed by measurement of specific radioactivity. The amount of measured radioactivity of the ³H-2-deoxyglucose was used as an indicator of the amount of glucose taken up by the cells.

(4) Results

In (1) above, pravastatin was administered to C57BL/6J mice for 15 weeks followed by measurement of blood glucose

levels and adiponectin concentrations. Adiponectin concentrations were measured in the same manner as Example 1. Although there were no significant differences in blood glucose levels between the pravastatin dose group and non-dose group, adiponectin concentrations in the dose group were 1.28 times higher than in the non-dose group.

[0043]

In the insulin tolerance test described in (2) above, the pravastatin dose group demonstrated significantly lower blood glucose levels than the non-dose group at 60 minutes after administration of insulin (non-dose group blood glucose level: 148 mg/dl, dose group blood glucose level: 110 mg/dl).

[0044]

In the C57BL/6J mouse adipocytes in (3) above, the pravastatin dose group demonstrated increased insulin sensitivity and increased glucose uptake more than the non-dose group. The amount of glucose uptake by the pravastatin dose group was 1.4 times greater than that by the non-dose group.

[0045]

From the aforementioned results, an HMG-CoA reductase inhibitor serving as an active ingredient of the present invention was found to enhance adiponectin production, to increase insulin sensitivity and to enhance insulin-induced glucose uptake, and was determined to be useful as a therapeutic or preventive agent of hypoadiponectinemia; an improving agent of insulin resistance; a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis; and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy,

nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome.

(Formulation Example 1) Tablets

After mixing 10 parts of pravastatin sodium, 71.55 parts of lactose, 20 parts of low substituted hydroxypropyl cellulose (LH21, Shin-Etsu Chemical), 20 parts of crystalline cellulose (Avicel PH101, Asahi Kasei) and 6.5 parts of magnesium metasilicate aluminate (Neusilin FL2, Fuji Chemical Industry) with a Henschel mixer (Mitsui Mining), 13 parts of a 10% aqueous solution of hydroxypropyl cellulose (Nippon Soda) and a suitable amount of water were added to the resulting mixture followed by kneading with a Henschel mixer. The resulting kneaded product was dried for 1 hour at 60°C with an air dryer. The resulting dried product was sized with a power mill (Dalton) equipped with a 1 mm ϕ diameter screen, and 129.35 parts of the resulting granules and 0.65 parts of magnesium stearate (NOF Corporation) were mixed with a V-mixer (Tokuju Seisakusho). The resulting mixture was formed into tablets to produce tablets having a diameter of 7.0 mm.

[Industrial applicability]

[0046]

The HMG-CoA reductase inhibitor serving as an active ingredient of the present invention is useful as a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract, and coronary artery disease), hypertension, obesity or arteriosclerosis, and a therapeutic or preventive agent of

diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, preferably a therapeutic or preventive agent of hypoadiponectinemia, an improving agent of insulin resistance, and a therapeutic or preventive agent of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract, and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia or insulin resistance syndrome, and more preferably a therapeutic or preventive agent of diabetes or arteriosclerosis caused by hypoadiponectinemia.
[Sequence listing free text]

[0047]

SEQ ID NO. 1: Adiponectin PCR primer

SEQ ID NO. 2: Adiponectin PCR primer

SEQ ID NO. 3: 36B4 PCR primer

SEQ ID NO. 4: 36B4 PCR primer

[Sequence listing]

SEQUENCE LISTING

<110> Shimomura, Iichiro

Matsuzawa, Yuji

Funahashi, Tohru

SANKYO COMPANY, LIMITED

<120> Adiponectin Production Enhancer

<130> 2004003KB

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Inventor: Shimomura, Iichiro

Inventor: Matsuzawa, Yuji

Inventor: Funahashi, Tohru

Inventor: Takagi, Toshiyuki

<220>

<223> Description of Artificial Sequence: An adiponectin
in PCR primer.

<400> 1

gatggcagag atggcactcc 20

<210> 2

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: An adiponectin
in PCR primer.

<400> 2

cttgccagtg ctgcggtcac 20

<210> 3

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: A 36B4 PCR
primer.

<400> 3

gctccaagca gatgcagca 19

<210> 4

<211> 18

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: A 36B4 PCR
primer.

2004-012265

<400> 4

ccggatgtga ggcagcag

18

[Name of Document] ABSTRACT

[Abstract]

[Object]

The present invention provides compounds having a superior adiponectin production enhancing action.

[Means for Solution]

The adiponectin production enhancement agent and medicaments contain an HMG-CoA reductase inhibitor.

[Selected drawing]

None

2004-012265

Acknowledged · Added information

Patent Application No.	2004-012265	
Receipt No.	504000091562	
Name of Document	Patent Application	
Examiner in charge	Senior Examiner Sec. 3	0092
Date of compiling	January 21, 2004	
[Acknowledged information · Added information]		
Filing date	January 20, 2004	

2004-012265

Information on Applicant's History

Identification Number	[503007759]
1. Date of Alteration	December 26, 2002
[Reason for Alteration]	Newly registered
Address	33-11, Higashitoyonakacho 1-chome, Toyonaka-shi, Osaka
Name	Ichiro SHIMOMURA

2004-012265

Information on Applicant's History

Identification Number	[599101070]
1. Date of Alteration	July 19, 1999
[Reason for Alteration]	Newly registered
Address	21-23, Hibarigaokayamate 2-chome, Takarazuka-shi, Hyogo
Name	Yuji MATSUZAWA

2004-012265

Information on Applicant's History

Identification Number	[503098528]
1. Date of Alteration	March 14, 2003
[Reason for Alteration]	Newly registered
Address	7-9, Takanodai 2-chome, Suita-shi, Osaka
Name	Tohru FUNAHASHI

2004-012265

Information on Applicant's History

Identification Number	[000001856]
1. Date of Alteration	August 15, 1990
[Reason for Alteration]	Newly registered
Address	5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo
Name	SANKYO COMPANY, LIMITED